Loading...

Ultra-LEAF™ Purified anti-human CD28 Antibody Ultra-LEAF™ Purified anti-human CD28 Antibody

Pricing & Availability
Clone
CD28.2 (See other available formats)
Regulatory Status
RUO
Workshop
V-CD28.05
Other Names
T44, Tp44
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
CD28dot2_LEAF_062107
Human peripheral blood lymphocytes stained with LEAF™ purified CD28.2, followed by anti-mouse IgGs FITC
  • CD28dot2_LEAF_062107
    Human peripheral blood lymphocytes stained with LEAF™ purified CD28.2, followed by anti-mouse IgGs FITC
  • CSFE_FSC-A_Antibody_FC_2_081213
    Human peripheral blood mononuclear cells were stained with CFSE on day 0, and then stimulated with (filled histogram) or without (open histogram) immobilized LEAF™ Purified CD3 (clone UCHT1) and LEAF™ purified CD28 (clone CD28.2) for 3 days. On day 4, cells were harvested and stained with CD4 Brilliant Violet 711™. Dot plot (above) was analyzed on live cells. Histogram data (below) was analyzed by gating on CD4 positive cells (above).
  • CSFE_FSC-A_Antibody_FC_3_081213
    Human peripheral blood mononuclear cells were stained with CFSE on day 0, and then stimulated with (filled histogram) or without (open histogram) immobilized LEAF™ Purified CD3 (clone UCHT1) and LEAF™ purified CD28 (clone CD28.2) for 3 days. On day 4, cells were harvested and stained with CD4 Brilliant Violet 711™. Dot plot (above) was analyzed on live cells. Histogram data (below) was analyzed by gating on CD4 positive cells (above).
Compare all formats
Cat # Size Price Quantity Check Availability Save
302960 100 mg SEK28418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302944 25 mg SEK11828
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302959 50 mg SEK19774
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302943 5 mg SEK4528
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302934 1 mg SEK1252
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302933 100 µg SEK924
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  2. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  3. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  4. Suwittayarak R, et al. 2022. Int J Mol Sci. 23: . PubMed
  5. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  6. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  7. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  8. Zheng X, et al. 2022. Cells. 12: . PubMed
  9. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  10. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  11. Yen M, et al. 2022. Cell. 185:1414. PubMed
  12. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  13. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  14. Piede N, et al. 2023. Cells. 12:. PubMed
  15. Solier S, et al. 2023. Nature. 617:386. PubMed
  16. Si W, et al. 2023. iScience. 26:106529. PubMed
  17. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  18. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  19. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  20. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  21. Chan W, et al. 2023. J Exp Med. :220. PubMed
  22. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  23. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  24. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  25. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  26. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  27. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  28. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  29. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  30. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  31. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  32. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  33. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  34. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  35. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  36. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  37. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  38. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  39. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  40. Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed
  41. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  42. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  43. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  45. Chan W, et al. 2021. Immunohorizons. 5:117. PubMed
  46. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  47. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  48. Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed
  49. Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed
  50. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  51. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  52. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  53. Lin M, et al. 2015. Immunol Lett. 165:26. PubMed
  54. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  55. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  56. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  57. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  58. Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed
  59. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  60. McBrien JB, et al. 2020. Nature. 578:154. PubMed
  61. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  62. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  63. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  64. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  65. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  66. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  67. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  68. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  69. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  70. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  71. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  72. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  73. Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed
  74. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  75. Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
  76. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  77. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  78. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  79. Suwittayarak R, et al. 2022. Int J Mol Sci. 23: . PubMed
  80. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  81. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  82. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  83. Zheng X, et al. 2022. Cells. 12: . PubMed
  84. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  85. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  86. Yen M, et al. 2022. Cell. 185:1414. PubMed
  87. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  88. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  89. Piede N, et al. 2023. Cells. 12:. PubMed
  90. Solier S, et al. 2023. Nature. 617:386. PubMed
  91. Si W, et al. 2023. iScience. 26:106529. PubMed
  92. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  93. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  94. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  95. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  96. Chan W, et al. 2023. J Exp Med. :220. PubMed
  97. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  98. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  99. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  100. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  101. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  102. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  103. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  104. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  105. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  106. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  107. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  108. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  109. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  110. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  111. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  112. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  113. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  114. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  115. Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed
  116. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  117. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  118. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  119. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  120. Chan W, et al. 2021. Immunohorizons. 5:117. PubMed
  121. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  122. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  123. Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed
  124. Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed
  125. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  126. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  127. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  128. Lin M, et al. 2015. Immunol Lett. 165:26. PubMed
  129. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  130. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  131. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  132. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  133. Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed
  134. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  135. McBrien JB, et al. 2020. Nature. 578:154. PubMed
  136. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  137. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  138. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  139. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  140. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  141. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  142. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  143. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  144. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  145. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  146. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  147. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  148. Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed
  149. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  150. Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
RRID
AB_2800749 (BioLegend Cat. No. 302960)
AB_2616668 (BioLegend Cat. No. 302944)
AB_2800748 (BioLegend Cat. No. 302959)
AB_2616667 (BioLegend Cat. No. 302943)
AB_11148949 (BioLegend Cat. No. 302934)
AB_11150591 (BioLegend Cat. No. 302933)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

View All CD28 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD28 (Maxpar® Ready) CD28.2 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD28 CD28.2 FC
Brilliant Violet 785™ anti-human CD28 CD28.2 FC
Brilliant Violet 650™ anti-human CD28 CD28.2 FC
Brilliant Violet 711™ anti-human CD28 CD28.2 FC
APC/Fire™ 750 anti-human CD28 CD28.2 FC
Alexa Fluor® 647 anti-human CD28 CD28.2 FC
TotalSeq™-A0386 anti-human CD28 CD28.2 PG
TotalSeq™-B0386 anti-human CD28 CD28.2 PG
TotalSeq™-C0386 anti-human CD28 CD28.2 PG
Brilliant Violet 605™ anti-human CD28 CD28.2 FC
APC/Cyanine7 anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Brilliant Violet 750™ anti-human CD28 CD28.2 FC
PE/Fire™ 810 anti-human CD28 CD28.2 FC
GMP PE anti-human CD28 CD28.2 FC
TotalSeq™-D0386 anti-human CD28 CD28.2 PG
Spark Violet™ 423 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Purified anti-human CD28 SF CD28.2 FC,Costim
GMP APC anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Biotin anti-human CD28 SF CD28.2 FC,Activ
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Spark Blue™ 515 anti-human CD28 CD28.2 FC
Spark Red™ 718 anti-human CD28 CD28.2 FC
GMP PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
APC/Fire™ 810 anti-human CD28 CD28.2 FC
Spark YG™ 581 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Spark YG™ 593 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark NIR™ 685 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark UV™ 387 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
APC anti-human CD28 CD28.2 FC
Biotin anti-human CD28 CD28.2 FC
FITC anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
PE/Cyanine5 anti-human CD28 CD28.2 FC
Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Alexa Fluor® 488 anti-human CD28 CD28.2 FC
Alexa Fluor® 700 anti-human CD28 CD28.2 FC
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Ultra-LEAF™ Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Brilliant Violet 421™ anti-human CD28 CD28.2 FC
Brilliant Violet 510™ anti-human CD28 CD28.2 FC
Go To Top Version: 5    Revision Date: 06-06-2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
CD28.2 (See other available formats)
Regulatory Status
RUO
Workshop
V-CD28.05
Other Names
T44, Tp44
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
CD28dot2_LEAF_062107
Human peripheral blood lymphocytes stained with LEAF™ purified CD28.2, followed by anti-mouse IgGs FITC
  • CD28dot2_LEAF_062107
    Human peripheral blood lymphocytes stained with LEAF™ purified CD28.2, followed by anti-mouse IgGs FITC
  • CSFE_FSC-A_Antibody_FC_2_081213
    Human peripheral blood mononuclear cells were stained with CFSE on day 0, and then stimulated with (filled histogram) or without (open histogram) immobilized LEAF™ Purified CD3 (clone UCHT1) and LEAF™ purified CD28 (clone CD28.2) for 3 days. On day 4, cells were harvested and stained with CD4 Brilliant Violet 711™. Dot plot (above) was analyzed on live cells. Histogram data (below) was analyzed by gating on CD4 positive cells (above).
  • CSFE_FSC-A_Antibody_FC_3_081213
    Human peripheral blood mononuclear cells were stained with CFSE on day 0, and then stimulated with (filled histogram) or without (open histogram) immobilized LEAF™ Purified CD3 (clone UCHT1) and LEAF™ purified CD28 (clone CD28.2) for 3 days. On day 4, cells were harvested and stained with CD4 Brilliant Violet 711™. Dot plot (above) was analyzed on live cells. Histogram data (below) was analyzed by gating on CD4 positive cells (above).
Compare all formats
Cat # Size Price Quantity Check Availability Save
302960 100 mg SEK28418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302944 25 mg SEK11828
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302959 50 mg SEK19774
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302943 5 mg SEK4528
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302934 1 mg SEK1252
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302933 100 µg SEK924
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  2. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  3. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  4. Suwittayarak R, et al. 2022. Int J Mol Sci. 23: . PubMed
  5. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  6. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  7. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  8. Zheng X, et al. 2022. Cells. 12: . PubMed
  9. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  10. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  11. Yen M, et al. 2022. Cell. 185:1414. PubMed
  12. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  13. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  14. Piede N, et al. 2023. Cells. 12:. PubMed
  15. Solier S, et al. 2023. Nature. 617:386. PubMed
  16. Si W, et al. 2023. iScience. 26:106529. PubMed
  17. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  18. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  19. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  20. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  21. Chan W, et al. 2023. J Exp Med. :220. PubMed
  22. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  23. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  24. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  25. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  26. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  27. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  28. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  29. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  30. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  31. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  32. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  33. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  34. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  35. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  36. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  37. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  38. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  39. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  40. Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed
  41. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  42. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  43. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  45. Chan W, et al. 2021. Immunohorizons. 5:117. PubMed
  46. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  47. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  48. Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed
  49. Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed
  50. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  51. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  52. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  53. Lin M, et al. 2015. Immunol Lett. 165:26. PubMed
  54. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  55. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  56. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  57. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  58. Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed
  59. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  60. McBrien JB, et al. 2020. Nature. 578:154. PubMed
  61. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  62. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  63. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  64. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  65. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  66. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  67. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  68. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  69. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  70. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  71. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  72. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  73. Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed
  74. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  75. Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
  76. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  77. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  78. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  79. Suwittayarak R, et al. 2022. Int J Mol Sci. 23: . PubMed
  80. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  81. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  82. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  83. Zheng X, et al. 2022. Cells. 12: . PubMed
  84. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  85. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  86. Yen M, et al. 2022. Cell. 185:1414. PubMed
  87. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  88. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  89. Piede N, et al. 2023. Cells. 12:. PubMed
  90. Solier S, et al. 2023. Nature. 617:386. PubMed
  91. Si W, et al. 2023. iScience. 26:106529. PubMed
  92. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  93. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  94. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  95. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  96. Chan W, et al. 2023. J Exp Med. :220. PubMed
  97. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  98. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  99. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  100. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  101. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  102. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  103. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  104. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  105. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  106. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  107. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  108. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  109. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  110. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  111. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  112. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  113. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  114. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  115. Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed
  116. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  117. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  118. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  119. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  120. Chan W, et al. 2021. Immunohorizons. 5:117. PubMed
  121. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  122. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  123. Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed
  124. Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed
  125. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  126. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  127. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  128. Lin M, et al. 2015. Immunol Lett. 165:26. PubMed
  129. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  130. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  131. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  132. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  133. Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed
  134. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  135. McBrien JB, et al. 2020. Nature. 578:154. PubMed
  136. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  137. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  138. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  139. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  140. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  141. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  142. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  143. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  144. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  145. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  146. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  147. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  148. Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed
  149. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  150. Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
RRID
AB_2800749 (BioLegend Cat. No. 302960)
AB_2616668 (BioLegend Cat. No. 302944)
AB_2800748 (BioLegend Cat. No. 302959)
AB_2616667 (BioLegend Cat. No. 302943)
AB_11148949 (BioLegend Cat. No. 302934)
AB_11150591 (BioLegend Cat. No. 302933)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

View All CD28 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD28 (Maxpar® Ready) CD28.2 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD28 CD28.2 FC
Brilliant Violet 785™ anti-human CD28 CD28.2 FC
Brilliant Violet 650™ anti-human CD28 CD28.2 FC
Brilliant Violet 711™ anti-human CD28 CD28.2 FC
APC/Fire™ 750 anti-human CD28 CD28.2 FC
Alexa Fluor® 647 anti-human CD28 CD28.2 FC
TotalSeq™-A0386 anti-human CD28 CD28.2 PG
TotalSeq™-B0386 anti-human CD28 CD28.2 PG
TotalSeq™-C0386 anti-human CD28 CD28.2 PG
Brilliant Violet 605™ anti-human CD28 CD28.2 FC
APC/Cyanine7 anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Brilliant Violet 750™ anti-human CD28 CD28.2 FC
PE/Fire™ 810 anti-human CD28 CD28.2 FC
GMP PE anti-human CD28 CD28.2 FC
TotalSeq™-D0386 anti-human CD28 CD28.2 PG
Spark Violet™ 423 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Purified anti-human CD28 SF CD28.2 FC,Costim
GMP APC anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Biotin anti-human CD28 SF CD28.2 FC,Activ
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Spark Blue™ 515 anti-human CD28 CD28.2 FC
Spark Red™ 718 anti-human CD28 CD28.2 FC
GMP PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
APC/Fire™ 810 anti-human CD28 CD28.2 FC
Spark YG™ 581 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Spark YG™ 593 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark NIR™ 685 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark UV™ 387 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
APC anti-human CD28 CD28.2 FC
Biotin anti-human CD28 CD28.2 FC
FITC anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
PE/Cyanine5 anti-human CD28 CD28.2 FC
Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Alexa Fluor® 488 anti-human CD28 CD28.2 FC
Alexa Fluor® 700 anti-human CD28 CD28.2 FC
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Ultra-LEAF™ Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Brilliant Violet 421™ anti-human CD28 CD28.2 FC
Brilliant Violet 510™ anti-human CD28 CD28.2 FC
Go To Top Version: 5    Revision Date: 06-06-2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account